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Abstract. Background: There are very few data regarding
inflammation in patients with intraductal papillary mucinous
neoplasms (IPMNs) of the pancreas. Aim: To evaluate the
circulating concentrations of placental growth factor (PlGF),
transforming growth factor-alpha (TGF-α), transforming
growth factor-beta1 (TGF-β1), tumour necrosis factor receptor
1 (TNF-R1) and matrix metalloproteinase-2 (MMP-2) in
patients with IPMNs and in those with pancreatic
adenocarcinomas. Patients and Methods: Sixty-nine patients
were enrolled: 23 (33.3%) had IPMNs and 46 (66.7%) had
histologically confirmed pancreatic adenocarcinomas. Thirteen
healthy subjects were also studied. PlGF, TGF-α, TGF-β1,
TNF-R1 and MMP-2 were determined using commercially
available kits. Results: TNF-R1 (p=0.003) was the only protein
significantly different among the three groups. Conclusion:
Serum TNF-R1 was elevated in patients with IPMNs and in
those with pancreatic adenocarcinomas, suggesting a high
apoptotic activity in both groups of patients studied.
Intraductal papillary mucinous neoplasms (IPMNs) of the
pancreas have received much clinical attention in the last
decade because they are slow-growing tumours which may be
cured surgically in most patients (1). However, there are only
few data regarding inflammation processes associated with this
disease. In contrast, there is notably more information available
about ductal adenocarcinomas of the exocrine pancreas.
Among the causes of the aggressive behaviour of IPMNs,
several passive and active strategies appear to be adopted by
tumour cells to circumvent antitumour immune defenses. They
include altered expression of major histocompatibility complex
(MHC) class I and II antigens (2), which may impair
interaction between malignant cells and potential tumour
cytotoxic T lymphocytes (CTLs), and resistance to apoptosis
through the Fas receptor pathway coupled with aberrant
expression of the ligand, which may be considered part of the
‘counterattack’ of the tumour cells against the immune effector
cells (3-5). Pancreatic carcinoma cells have also been shown to
spontaneously secrete immunosuppressive cytokines, such as
interleukin-10 and transforming growth factor-beta (TGF-β),
which downregulate the host immune system and contribute to
a systemic T helper 2 immune phenotype in vivo (3, 6); thus,
cytokines play a pivotal role in the induction of cell mediated
and humoral immunity (7).
Of several circulating substances which can be evaluated
in patients with cancer, this study aimed to evaluate the
following: placental growth factor (PlGF) (an angiogenesis-
related factor (8)), transforming growth factor-alpha (TGF-
α), transforming growth factor-beta1 (TGF-β1) (since TGF-
α acts synergistically with TGF-β in inducing phenotypic
tumoural transformation (9)), tumour necrosis factor receptor
1 (TNF-R1) (member of the TNFR superfamily, which is
able to regulate a broad array of developmental processes
and plays a pivotal role in numerous biological events in
mammals, including induction of apoptosis, survival,
differentiation and proliferation of cells (10)) and matrix
metalloproteinase-2 (MMP-2) (which is a part of a family of
proteolytic enzymes capable of degrading several substrates
within the extracellular matrix, which is an essential step in
the processes of invasion and metastasis (11)). All these
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substances have been studied previously in pancreatic ductal
adenocarcinomas, mainly in pathological specimens, but not
in patients with pancreatic IPMNs. Thus, the aims of the
present study were to evaluate the circulating concentrations
of PlGF, TGF-α, TGF-β1, TNF-R1 and MMP-2 in malignant
diseases of the pancreas, such as IPMNs and pancreatic
adenocarcinomas, and also to evaluate the concentrations of
these molecules in comparison with an established serum
marker of pancreatic cancer such as the carbohydrate antigen
19-9 (CA 19-9).
Patients and Methods
Patients. Consecutive patients eighteen years of age or older who
were admitted to the Unit for the Study of Pancreatic Diseases of
Sant’Orsola-Malpighi Hospital of Bologna (Italy) for exocrine
pancreatic neoplasms between October 2007 and March 2009 were
eligible for the study. 
A total of 69 patients (39 males, 30 females, mean age:
69.8±10.4 years) were enrolled: 23 (33.3%) had IPMNs and 46
(66.7%) had histologically confirmed pancreatic adenocarcinomas;
the demographic and clinical characteristics of the patients studied
are reported in Table I. The body mass index (BMI) was stratified
according to the WHO classification (12) and pancreatic
insufficiency was defined as faecal elastase-1 concentrations less
than 200 μg/g (13). At the time of the study, none of the patients
had had any treatment for their disease. Of the 23 patients with
IPMNs, 10 (43.5%) had branch type IPMNs and the remaining 13
(56.5%) had main duct type IPMNs. 
Finally, 13 blood donors were also studied as healthy controls (7
males, 6 females, p=1.000 vs. all patients; mean age: 57.0±14.6
years, p=0.003 vs. all patients).
Methods. Blood specimens were obtained in the morning in a
fasting state from each subject. Laboratory personnel were unaware
of the clinical diagnoses or the details of the patient clinical history.
The serum specimens were stored at –20˚C until analysis.
PlGF, TGF-α, TGF-β1, TNF-R1 and MMP-2 were determined
using commercially available kits (R&D Systems, Minneapolis,
MN, USA). The intra-assay CVs were <3.9% and the inter-assay
CVs were <7.9%. The reference limits used were: 0.2-26 pg/ml for
PlGF, 0.5-32 pg/ml for TGF-α, 18,289-63,416 pg/ml for TGF-β1,
749-1,966 pg/ml for TNF-R1 and 117-410 ng/ml for MMP-2.
Furthermore, CA 19-9 was also assayed using an electrochemical
luminescence immunoassay (reference limits: 0-37 U/ml).
Ethics. The study was approved by the Clinical Committee of the
Department of Internal Medicine of Sant’Orsola Hospital of
Bologna (Italy) and was carried out in accordance with the Helsinki
Declaration of the World Medical Association. All subjects gave
written informed consent to participate in the study.
Statistical analysis. Means, standard deviations and frequencies
were used as descriptive statistics. Data were analysed by means of
non-parametric tests: Kruskal-Wallis test, Spearman rank
correlation, Fisher’s exact test, Pearson chi-square, and linear-by-
linear association chi-square. SPSS v. 13.0 (SPSS Inc., Chicago, IL,
USA) was used to analyse the data. Two-tailed p-values of less than
0.05 were considered statistically significant.
Results
The two groups of patients were not statistically different
regarding the gender (p=0.797), age (p=0.165) and
localisation of the tumour (p=0.174), whereas the BMI of
patients with pancreatic ductal adenocarcinomas was
significantly lower than that of patients having IPMNs
(p=0.010; Table I). In addition, the frequencies of metastases
(p<0.001), pain (p<0.001), jaundice (p=0.001) and diabetes
(p<0.001) were significantly higher in patients with
pancreatic ductal adenocarcinomas than in those having
IPMNs. The frequency of pancreatic exocrine insufficiency
at the time of the study and the frequency of patients who
underwent pancreatic surgery after the diagnosis were not
different between the groups of patients studied (p=1.000
and p=0.797, respectively).
The mean and standard deviation values of serum
concentrations of PlGF, TGF-α, TGF-β1, TNF-R1, MMP-2
and CA 19-9 in the two patient groups and the healthy
subjects studied are reported in Table II.
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Table I. Demographic and clinical characteristics of the patients with
malignant pancreatic diseases according to the final diagnosis. Data








Male 14 (60.9%) 25 (54.3%)
Female 9 (39.1%) 21 (45.7%)
Age (years) 72.1±7.6 68.6±11.5 0.165b
Body mass index (kg/m2) 22.4±1.9 20.8±3.0 0.010b
BMI classes
Underweight (<18.5 kg/m2) - 12 (26.1%) 0.062c
Normal (18.5-24.9 kg/m2) 22 (95.7%) 32 (69.6%)
Pre-obese (25-29.9 kg/m2) 1 (4.3%) 1 (2.2%)
Obese (30 kg/m2 or more) - 1 (2.2%)
Localisation
Head 15 (65.2%) 36 (78.3%) 0.174d
Body 1 (4.3%) 4 (8.7%)
Body/tail 0 2 (4.3%)
Tail 3 (13.0%) 2 (4.3%)
Diffuse 4 (17.4%) 2 (4.3%)
Metastasis 2 (8.7%) 31 (67.4%) <0.001a
Pain 4 (17.4%) 44 (95.7%) <0.001a
Jaundice 3 (13.0%) 26 (56.5%) 0.001a
Diabetes 8 (34.8%) 40 (87.0%) <0.001a
Pancreatic insufficiency 7 (30.4%) 14 (30.4%) 1.000a
Pancreatic surgery 9 (39.1%) 21 (45.7%) 0.797a
aFisher’s exact test; bKruskal-Wallis test; clinear-by-linear association
chi-square; dPearson chi-square.
The only two parameters showing significant differences
among the three groups were TNF-R1 (p=0.003) and CA 19-
9 (p=0.007). In particular, TNF-R1 concentrations were
significantly higher in both patient groups than in healthy
subjects (IPMN, p=0.004; pancreatic adenocarcinoma,
p=0.001). In contrast, serum CA 19-9 concentrations were
significantly higher in patients with pancreatic adeno-
carcinomas than in those with IPMNs (p=0.044) and healthy
subjects (p=0.003). It should be noted that a serum CA 19-
9 concentration of 23,688 U/ml was found in one patient
with a main duct IPMN and distant metastases; in the other
22 patients, CA 19-9 serum concentrations were 172±269
U/ml (mean±SD) and ranged from 0.53 to 1,151 U/ml.
The significance of the relationships between the clinical
parameters and the serum concentrations of TNF-R1 and CA
19-9 are reported in Table III. Within the group of patients
with pancreatic adenocarcinomas, patients with metastases
had serum concentrations of TNF-R1 significantly higher
than those without (p=0.034) (Figure 1). 
Discussion
It is well known that patients with pancreatic
adenocarcinomas have a poor outcome; on the other hand,
IPMNs of the pancreas are slow-growing neoplasms which
may be cured surgically in most patients (1). The differences
between the two neoplasms are also confirmed by the
clinical data of this study. In fact, patients with ductal
adenocarcinomas had a frequency of pain, diabetes, jaundice
and metastases that was significantly higher than those with
IPMNs, as well as a significantly lower BMI. Unfortunately,
in this study, only few data were available regarding
inflammation in pancreatic IPMNs. Thus, the present study
evaluated PlGF, TGF-α, TGF-β1, TNF-R1 and MMP-2 in
patients with malignant chronic diseases of the pancreas,
such as pancreatic adenocarcinomas and IPMNs, since a
better understanding of the basis of molecular cross-talk
between tumour cells and the immune system will be helpful
in developing immunotherapeutic approaches to pancreatic
neoplasms, motivated by the lack of conventional immune
therapeutic options for these patients, especially for those
having an IPMN. 
PlGF is implicated in several pathological processes,
including the growth and spread of cancer. In agreement
with a previous report (14), this study found that the
serum levels of PlGF in both patient groups (those with
pancreatic adenocarcinomas and those with IPMNs) were
not significantly different from those in control subjects.
These results are not surprising given that PlGF has been
associated with arteriogenesis (15) and it is up-regulated
after anti-vascular endothelial factor therapy as this
substance is involved in the rapid restoration of the
tumour blood supply after treatment (16). Thus, in this
study, the patients were not medically treated at the time
of the study and this explains, at least in part, the results
obtained.
A behaviour similar to that of PlGF was found for TGF-
α, TGF-β1 and MMP-2. In particular, TGF-α is involved in
cancer progression. Gastrointestinal cancer cells produce
and secrete TGF-α in vitro (17), and immunohistochemical
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Table II. Circulating levels of the various moleades studied in the three
groups of subjects. Data are reported as mean±SD and the Kruskal-
Wallis test was applied.






PlGF (pg/ml) 21.6±19.7 18.9±16.3 30.1±25.6 0.499
TGF-α (pg/ml) 19.3±25.8 21.0±38.3 1.8±1.2 0.153
TGF-β1 (pg/ml) 14,132±4,074 14,298±4,452 15,732±3,089 0.408
TNF-R1 (ng/ml) 1,987±940b 1,872±722a 1,170±505 0.003
MMP-2 (ng/ml) 280±78 267±68 233±73 0.237
CA 19-9 (U/ml) 1,237±4,905* 1,268±2,828$c 21.4±8.8 0.007
§Comparisons among the three groups of patients studied; ap=0.001;
bp=0.004; cp=0.003: vs. healthy subjects; $p=0.044 vs. intraductal
papillary mucinous neoplasms; *One patient had serum CA 19-9
concentrations of 23,688 U/ml. In the other 22 patients, CA 19-9 serum
concentrations ranged from 0.53 to 1,151 U/ml, with a mean value±SD
of 172±269 U/ml.
Table III. The significance of the relationships between the clinical
parameters and the serum concentrations of TNF-R1 and CA 19-9 in
23 patients with pancreatic intraductal papillary mucinous neoplasms
(IPMNs) and in 46 patients with pancreatic adenocarcinomas (ADACs).
The Kruskal-Wallis test was applied (with the exception of BMI) and the
significant p-values are reported in bold.
TNF-R1 CA 19-9
IPMN ADAC IPMN ADAC
Gender (males vs. females) 0.166 0.100 0.257 0.749
Class of BMIa 0.098 0.209 0.559 0.489
Localisation of the tumour 0.669 0.553 0.553 0.484
Metastases (yes vs. no) 0.585 0.034 0.081 0.648
Pain (yes vs. no) 0.417 0.332 1.000 0.085
Jaundice (present vs. absent) 0.201 0.063 0.235 0.947
Diabetes (yes vs. no) 0.220 0.514 0.156 0.744
Pancreatic exocrine insufficiency 
(yes vs. no) 0.204 0.053 0.204 0.305
Pancreatic surgery (yes vs. no) 0.801 0.051 0.801 0.087
Branch type vs. main duct type 0.495 - 0.620 -
aSpearman rank correlation.
staining of sections of human tumours has shown that these
tumours express TGF-α (18). Thus, the tumours themselves
may contribute to the increase in TGF-α. This study
confirmed the previously reported results showing that
TGF-α is a normal constituent of human serum (19),
lending support to the hypothesis that TGF-α plays a role
as a growth factor in normal cellular physiology. TGF-α is
also thought to play a role in inflammatory response (20)
and wound healing (21). Thus, physiological response to
the presence of tumours, to treatment or to both may also
contribute to increased serum TGF-α levels in these
patients. 
Regarding TGF-β1, it was found that serum
concentrations of this substance in the patients with
pancreatic adenocarcinomas were not significantly
different from those found in patients with IPMNs and in
healthy subjects; the mechanisms linking levels of serum
TGF-β1 and pancreatic cancer are unclear because of the
complex, dual role of TGF-β in carcinogenesis (22).
Furthermore, TGF-β is produced by and can act on nearly
every cell type and on normal cells; thus, it is possible
that, in humans, elevated concentrations of this substance
can be found in pancreatic tissue (23) but not in the
circulation. Another possible explanation is that TGF-β is
involved in the process of carcinogenesis (24) and, when
the cancer becomes evident, its serum levels tend to
normalise.
The overexpression of MMP-2 has largely been
described in human tumours and the presence of its active
form at the invasion front correlates with its invasive
potential (25). Immunohistochemical studies showed MMP-
2 in tumoural as well as in stromal cells, whereas in situ
hybridisation demonstrated MMP-2 mRNA in stromal cells
(26). It has been suggested that peritumoural fibroblasts
deliver MMP-2 to cancer cells which could bind (27) and
activate gelatinase A. To date, there have been no studies
on the circulating levels of this molecule in pancreatic
cancer patients to the authors knowledge. This study found
its circulating levels to be similar in pancreatic cancer
patients and in healthy subjects. Furthermore, they were
also similar in patients with IPMNs and in those with
pancreatic adenocarcinomas. 
The biological activities of TNF are mediated through
two TNF receptors (TNF-Rs), namely TNF-R1 and TNF-
R2. TNFR trimerisation is necessary for the functional
activities mediated by the receptors, and this self-assembly
occurs in the absence of the ligand (28). Engagement of
TNF-R1 by TNF activates several transcription factors
which include NF-κB and c-Jun/activator protein 1, leading
to upregulation of a large number of genes involved in
inflammatory and immune responses (29, 30). To date,
TNF-R1 signaling studies have been difficult to perform
due to the proapoptotic consequences of overexpression,
and some researchers have resorted to the use of
cytoplasmic truncations of TNF-R1 which do not reflect the
physiological events or the natural structure of these
molecules (31). Furthermore, the identification of the
proteins involved in the control of apoptosis may provide
leads for novel therapeutic approaches; finally, there are no
studies exploring the behaviour of TNF-R1 in patients with
pancreatic neoplasms. Thus, the circulating levels of this
substance were evaluated in adenocarcinoma patients and
IPMN patients and it was found that serum concentrations
of TNF-R1 were significantly higher in both patients with
pancreatic adenocarcinomas and those with IPMNs as
compared to the control subjects, suggesting a high
apoptotic activity both in patients with adenocarcinomas
and those with IPMNs. Most importantly, the serum levels
of TNF-R1 in patients with pancreatic adenocarcinomas
were higher in patients with metastases than in those
without, suggesting that this protein may be utilised in
clinical practice for selecting those patients who can be
surgically resected. 
The relatively small sample size in each group may be
considered as a weakness of this study; however, it should
be noted that exocrine pancreatic neoplasms have not a
high incidence and that the patients were consecutively
enrolled.
In conclusion, serum TNF-R1 was elevated in patients
with IPMNs and in those with pancreatic adenocarcinomas
suggesting a high apoptotic activity in both groups of
patients studied; further studies should be performed in order
to confirm the findings that serum TNF-R1 is also a
potentially good marker for selecting patients with pancreatic
ductal adenocarcinomas having distant metastases.
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Figure 1. Distribution of TNF-R1 in patients with pancreatic
adenocarcinomas with and without metastases. The Kruskal-Wallis test
was applied. Mean and SD values are also shown.
References
1 Fritz S, Warshaw AL and Thayer SP: Management of mucin-
producing cystic neoplasms of the pancreas. Oncologist 14: 125-
36, 2009.
2 Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T,
Zamboni G, Martignoni G, Lemoine NR, Scarpa A and Accolla
RS: Expression of MHC class I and class II antigens in
pancreatic adenocarcinomas. Tissue Antigens 48: 301-311, 1996.
3 Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A,
Tibaudi D, Robecchi A, Emanuelli G and Rodeck U: Tumor-
associated transforming growth factor-beta and interleukin- 10
contribute to a systemic Th2 immune phenotype in pancreatic
carcinoma patients. Am J Pathol 155: 537-547, 1999.
4 Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D,
Kremer B and Kalthoff H: Human pancreatic adenocarcinomas
express Fas and Fas ligand yet are resistant to Fas-mediated
apoptosis. Cancer Res 58: 1741-1749, 1998.
5 von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC,
Sadanaga N, Wood I, Peiper M, Goedegebuure PS and Eberlein
TJ: Pancreatic cancer cells can evade immune surveillance via
nonfunctional Fas (APO-1/CD95) receptors and aberrant
expression of functional Fas ligand. Surgery 125: 73-84, 1999.
6 von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk
C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and
local immunosuppression in pancreatic cancer patients. Clin
Cancer Res 7(Suppl): 925s-932s, 2001.
7 Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino
A, Dughera L, Robecchi A, Pirisi M and Emanuelli G: Cytokine
expression profile in human pancreatic carcinoma cells and in
surgical specimens: implications for survival. Cancer Immunol
Immunother 55: 684-698, 2006.
8 Schomber T, Kopfstein L, Djonov V, Albrecht I, Baeriswyl V,
Strittmatter K and Christofori G: Placental growth factor-1
attenuates vascular endothelial growth factor-A-dependent tumor
angiogenesis during beta cell carcinogenesis. Cancer Res 67:
10840-10848, 2007.
9 Booth BW, Jhappan C, Merlino G and Smith GH: TGFbeta1 and
TGFalpha contrarily affect alveolar survival and tumorigenesis in
mouse mammary epithelium. Int J Cancer 120: 493-499, 2007.
10 Grewal IS: Overview of TNF superfamily: a chest full of
potential therapeutic targets. Adv Exp Med Biol 647: 1-7, 2009.
11 Bramhall SR, Neoptolemos JP, Stamp GW and Lemoine NR:
Imbalance of expression of matrix metalloproteinases (MMPs)
and tissue inhibitors of the matrix metalloproteinases (TIMPs)
in human pancreatic carcinoma. J Pathol 182: 347-55, 1997.
12 WHO: Obesity: preventing and managing the global epidemic.
WHO Technical Report Series 894 Geneva 2000.
13 Pezzilli R, Barassi A, Morselli-Labate AM, Fantini L, Tomassetti P,
Campana D, Casadei R, Finazzi S, d'Eril GM and Corinaldesi R:
Fecal calprotectin and elastase 1 determinations in patients with
pancreatic diseases: a possible link between pancreatic insufficiency
and intestinal inflammation. J Gastroenterol 42: 754-760, 2007.
14 Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC,
Tsao PN, Jan IS and Wong JM: Serum vascular endothelial
growth factor/soluble vascular endothelial growth factor receptor
1 ratio is an independent prognostic marker in pancreatic cancer.
Pancreas 37: 145-150, 2008.
15 Roy H, Bhardwaj S and Ylä-Herttuala S: Biology of vascular
endothelial growth factors. FEBS Lett 580: 2879-2887, 2006.
16 Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M and Van
Damme N: Antiangiogenic versus cytotoxic therapeutic approaches
in a mouse model of pancreatic cancer: an experimental study with
a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and
radiotherapy. Oncol Rep 22: 105-113, 2009.
17 Smith J, Derynck R and Korc M: Production of transforming growth
factor a in human pancreatic cells: evidence for a superagonist
autocrine cycle. Proc NatI Acad Sci USA 84: 7567-7570, 1987.
18 Tahara E: Growth factors and oncogenes in human gastrointestinal
carcinomas. J Cancer Res Clin Oncol 116: 121-131, 1990.
19 Moskal TL, Huang S, Ellis LM, Fritsche HA Jr. and Chakrabarty
S: Serum levels of transforming growth factor alpha in
gastrointestinal cancer patients. Cancer Epidemiol Biomarkers
Prev 4: 127-131, 1995.
20 Ellingsworth I, Derynck R and Voorhees I: Overexpression of
transforming growth factor a in psoriatic epidermis. Science 243:
811-814, 1989.
21 Schultz G, Rotatori D and Clark W: EGF and TGF-α in wound
healing and repair. J Cell Biochem 45: 350-352, 1991.
22 Piek E and Roberts AB: Suppressor and oncogenic roles of
transforming growth factor-β and its signaling pathways in
tumorigenesis. Adv Cancer Res 83: 1-54, 2001.
23 Kleeff J, Friess H, Simon P, Susmallian S, Büchler P,
Zimmermann A, Büchler MW and Korc M: Overexpression of
Smad2 and colocalization with TGF-beta1 in human pancreatic
cancer. Dig Dis Sci 44: 1793-1802, 1999.
24 Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y,
Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T and JACC
Study Group: Serum transforming growth factor-beta1 levels and
pancreatic cancer risk: a nested case-control study (Japan).
Cancer Causes Control 17: 1077-1082, 2006.
25 Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell
interactions with the extracellular matrix during invasion and
metastasis. Ann Rev Cell Biol 9: 541-573, 1993.
26 Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone
C and Clement B: In situ detection of MMP-2 and TIMP-2
transcripts in human primary hepatocellular carcinoma and liver
metastasis. J Hepatol 26: 593-605, 1997.
27 Emonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler-
Stevenson WG and Foidart JM: Tumor cell surface-associated
binding site for the Mr 72,000 type IV collagenase. Cancer Res
52: 5845-5848, 1992.
28 Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL and Lenardo
MJ: A domain in TNF receptors that mediates ligand-independent
receptor assembly and signaling. Science 288: 2351-2354, 2000.
29 Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko
AV and Boldin MP: Tumor necrosis factor receptor and Fas
signaling mechanisms. Annu Rev Immunol 17: 331-367, 1999.
30 MacEwan DJ: TNF ligands and receptors: a matter of life and
death. Br J Pharmacol 135: 855-875, 2002. 
31 Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner
MD, Hitman GA, McDermott MF and Chernajovsky Y: Tumor
necrosis factor receptor I from patients with tumor necrosis factor
receptor-associated periodic syndrome interacts with wild-type
tumor necrosis factor receptor I and induces ligand-independent NF-
kappaB activation. Arthritis Rheum 52: 2906-2916, 2005.
Received May 12, 2010
Revised June 1, 2010
Accepted June 8, 2010
Pezzilli et al: Inflammation and Pancreatic Neoplasms
3805
